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Severe traumatic injury is frequently associated with 
hemorrhagic shock necessitating massive transfusions. 
Patients frequently become coagulopathic because of the 
combination of dilution of platelets and clotting factors, 
metabolic acidosis, hypothermia, and consumption of 
clotting factors. Although replacement of blood loss with 
fresh whole blood would be ideal, this is not possible in 
civilian situations under current blood-banking practices. 
Standard therapy involves the administration of packed 
red blood cells (PRBCs), fresh frozen plasma (FFP), plate-
lets, and cryoprecipitate. Th   e last of these is administered 
primarily to replete ﬁ   brinogen, which is commonly 
decreased by dilution as well as consumption. In the 
previous issue of Critical Care, Grottke and colleagues 
[1] explored the potential use of a ﬁ  brinogen concentrate 
instead.
Although these blood products are life-saving, they do 
have risks. In general, the more blood products adminis-
tered, particularly PRBCs and FFP, the greater the risk for 
multiple organ system dysfunction and mortality [2-4]. 
Immunologic responses appear to play a major role.
In contrast, recent studies have suggested a beneﬁ  cial 
eﬀ   ect of cryoprecipitate administration. In a military 
population of patients receiving massive transfusions, the 
ratio of ﬁ  brinogen (from all blood products) to PRBCs 
transfused was associated with reduced mortality [5]. 
Similarly, in a large database of civilians, administration 
of cryoprecipitate was associated with a decreased risk of 
multiple organ dysfunction [2].
Fibrinogen plays a critical role in hemostasis as it 
promotes platelet aggregation and, when activated to form 
ﬁ   brin, provides the substrate for red blood cells and 
platelets to form strong clots. In theory, administration of 
exogenous ﬁ  brinogen when the endogenous levels are low 
could bypass missing components of the clotting cascade.
Grottke and colleagues [1] have explored the use of 
diﬀ  erent doses of a ﬁ  brinogen concentrate to correct the 
coagulopathy caused by hemodilution and to decrease 
bleeding in a clinically relevant animal model of trauma 
and hemorrhagic shock. Th   is work builds upon the work 
of Fries and colleagues [6], which used a larger dose of 
ﬁ  brinogen. Fries and colleagues found a dose-dependent 
improvement in standard clotting studies and thrombo-
elasto  grams (TEGs). Even with a relatively low dose, the 
authors found decreased bleeding and improved survival 
compared with controls. Th   ey also found no evidence of 
harm from the ﬁ  brinogen administration.
Th   e model used in the study by Grottke and colleagues 
seems to be well designed to explore questions related to 
trauma and coagulopathy. Th  e liver injury simulates 
severe trauma with active bleeding, which can be 
quantiﬁ  ed. Coagulopathy is induced by hemodilution in a 
way that may be typical of the clinical situation of massive 
transfusion and ﬂ  uid resuscitation without replacement 
of plasma, ﬁ  brinogen, or platelets. Th  e use of the Cell 
Saver® (Haemonetics, Braintree, MA, USA), which might 
be used clinically to salvage and re-infuse the animals’ 
red blood cells, further simulates clinical situations. Th  e 
only aspect of the model that is not clinically relevant is 
timing since the coagulopathy and ﬁ  brinogen concentrate 
administration precede hemorrhage. Th   is limitation does 
not detract from the utility of the model or the 
importance of the ﬁ  ndings.
Th   e results of this study [1] suggest that replacement of 
ﬁ  brinogen to a certain threshold level, perhaps as low as 
70 mg/dL, is suﬃ     cient to provide hemostasis. Since 
ﬁ  brino  gen needs to be activated to have an eﬀ  ect, it is 
intriguing and important to recognize that, even with 
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be present. Because of the question of activators, the 
authors see ﬁ   brinogen administration as adjunctive 
therapy to be used concomitantly with replacement of 
other coagulation factors.
Th  ough not discussed much in the current paper, 
signiﬁ    cant clinical experience with the ﬁ  brinogen concen-
trate used in this study has been reported. Th   e product is 
clinically approved for use in patients with congenital 
ﬁ  brinogen deﬁ  ciency and seems to have a good safety 
proﬁ   le [7]. As a result, oﬀ  -label use has already been 
reported. Fenger-Eriksen and colleagues [8] found that 
use of the ﬁ   brino  gen concentrate improved standard 
clotting studies, increased ﬁ   brinogen levels, and 
decreased bleed  ing in patients with massive hemorrhage 
and decreased ﬁ   brino  gen levels. Others have shown 
improved coagulation studies and decreased bleeding after 
cardiac [9], urologic [10], and orthopedic [11] surgery.
A secondary ﬁ   nding in this study is that standard 
clotting studies may not represent clinical hemostatic 
function as these normalized while the TEG remained 
abnormal. Th  is  ﬁ  nding is in agreement with others [12,13] 
and demonstrates the complexities in objectively monitor-
ing coagulation with severe hemorrhage, hemodilution, 
and massive transfusions.
So where do we go from here? Grottke and colleagues 
[1] give us some guidance in this regard, recommending 
clinical studies of optimum level, need for combination 
therapy, timing, and patient selection. As far as the use of 
ﬁ  brinogen concentrates for patients with massive hemor-
rhage is concerned, there seem to be suﬃ   cient preclinical 
and preliminary clinical data to warrant a pivotal clinical 
trial in patients with massive hemorrhage. Th  e work by 
Grottke and colleagues [1], as well as by others, gives us 
good data for dosing of ﬁ  brinogen concen  trate and for 
minimal ﬁ   brinogen levels to be achieved. Trauma 
patients in hemorrhagic shock would be an appropriate 
target population. It may be that focused restitution of 
ﬁ  brinogen levels with a ﬁ  brinogen concentrate is more 
eﬃ   cient and eﬃ   cacious than the use of cryoprecipitate or 
other blood products. Although it is unlikely that 
ﬁ  brinogen will be a magic bullet, it may be an excellent 
adjunct to blood component replacement.
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